BRPI0616993A2 - bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas - Google Patents

bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas Download PDF

Info

Publication number
BRPI0616993A2
BRPI0616993A2 BRPI0616993-7A BRPI0616993A BRPI0616993A2 BR PI0616993 A2 BRPI0616993 A2 BR PI0616993A2 BR PI0616993 A BRPI0616993 A BR PI0616993A BR PI0616993 A2 BRPI0616993 A2 BR PI0616993A2
Authority
BR
Brazil
Prior art keywords
product
probiotic bacteria
obesity
probiotic
group
Prior art date
Application number
BRPI0616993-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kajsa Ohlson
Margit Mahlapuu
Ulla Svensson
Original Assignee
Arla Foods Amba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0616993(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arla Foods Amba filed Critical Arla Foods Amba
Publication of BRPI0616993A2 publication Critical patent/BRPI0616993A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0616993-7A 2005-10-07 2006-10-02 bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas BRPI0616993A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
SE0502214-0 2005-10-07
PCT/SE2006/001117 WO2007043933A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity

Publications (1)

Publication Number Publication Date
BRPI0616993A2 true BRPI0616993A2 (pt) 2011-07-05

Family

ID=37943064

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616993-7A BRPI0616993A2 (pt) 2005-10-07 2006-10-02 bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas

Country Status (16)

Country Link
US (1) US20080267933A1 (enExample)
EP (2) EP2431044B1 (enExample)
JP (1) JP2009511469A (enExample)
CN (1) CN101287478B (enExample)
AU (1) AU2006299956B2 (enExample)
BR (1) BRPI0616993A2 (enExample)
CA (1) CA2624890A1 (enExample)
CY (1) CY1113704T1 (enExample)
DK (2) DK1945235T3 (enExample)
EA (1) EA015461B1 (enExample)
ES (2) ES2396865T3 (enExample)
PL (1) PL1945235T3 (enExample)
PT (1) PT1945235E (enExample)
SE (1) SE529185C2 (enExample)
SI (1) SI1945235T1 (enExample)
WO (1) WO2007043933A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008134892A (ru) 2006-01-27 2010-03-10 Даниско А/С (Dk) Применение пробиотичеких микроорганизмов для лечения и профилактики ожирения и связанных с ним расстройств
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
EP2173182A1 (en) * 2007-07-25 2010-04-14 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
JP5225652B2 (ja) * 2007-10-29 2013-07-03 雪印メグミルク株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
FR2930264B1 (fr) * 2008-04-18 2013-02-22 Gervais Danone Sa Nouvelle souche de lactobacillus paracasei subsp. paracasei dotee de proprietes antimicrobiennes et immunomodulatrices.
DK2123168T3 (da) * 2008-05-16 2012-04-10 Nestec Sa Lactobacillus paracasei og vægtkontrol
BRPI0912774A2 (pt) * 2008-05-19 2017-05-23 Nestec Sa métodos para reduzir absorção de lipídio por um animal
CN102300569A (zh) * 2008-08-15 2011-12-28 雀巢产品技术援助有限公司 促进能量代谢的方法
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
RU2011135505A (ru) * 2009-03-06 2013-04-20 Федерасьон Де Продюктер Асериколь Дю Кебек Симбиотические композиции продукта из клена и способы
BRPI0924418A2 (pt) * 2009-03-10 2018-10-16 Jinis Biopharmaceuticals Co. composições e métodos para a prevenção e o tratamento de obesidade e síndrome metabólica relacionada à obesidade
CN102448477A (zh) * 2009-03-25 2012-05-09 科·汉森有限公司 益生菌在调节体重中的用途
EP2411026A1 (en) 2009-03-25 2012-02-01 Chr. Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
WO2010146568A2 (en) * 2009-06-19 2010-12-23 Danisco A/S Bifidobacteria for treating diabetes and related conditions
JP5436991B2 (ja) * 2009-09-10 2014-03-05 国立大学法人北海道大学 ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
RU2546251C2 (ru) 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
JP5801802B2 (ja) * 2010-06-08 2015-10-28 カルピス株式会社 脂質代謝改善剤
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
AU2012325072B2 (en) * 2011-10-18 2015-12-03 Société des Produits Nestlé S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
JP2016507216A (ja) 2012-11-12 2016-03-10 コンパニ・ジェルベ・ダノンＣｏｍｐａｇｎｉｅ Ｇｅｒｖａｉｓ Ｄａｎｏｎｅ 体脂肪の蓄積を低減させるためのラクトバチルスラムノサス株
ES2684074T3 (es) * 2013-04-17 2018-10-01 Suntory Holdings Limited Composición que contiene una bacteria que pertenece al género Lactobacillus
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
KR101545551B1 (ko) 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
EP3104868A2 (fr) * 2014-02-14 2016-12-21 Vesale Pharma Sa Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
WO2016020488A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Myo-inositol and probiotics and uses
CN104186655B (zh) * 2014-08-27 2016-06-29 内蒙古伊利实业集团股份有限公司 具有降血脂及抗氧化功能的低脂发酵乳及其制备方法
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
DK3387156T3 (da) * 2015-12-11 2020-08-03 Prec Group Limited Lactobacillus casei til behandling af fedme og associerede metabolske sygdomme
RU2762096C2 (ru) * 2016-04-14 2021-12-15 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Бифидобактерии для снижения потребления пищи, энергии и/или жиров
WO2018145294A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
TWI640313B (zh) * 2017-08-18 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制肥胖之用途
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
FR3095761B1 (fr) 2019-05-06 2023-11-10 Lab Attitude Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
US20230042693A1 (en) 2019-12-27 2023-02-09 Biopolis, S.L. Uses of lipoteichoic acid from bifidobacteria
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
FR3125945B1 (fr) 2021-08-03 2024-07-12 Setalg Composition pour protéger un microorganisme dans un environnement acide.
KR102445708B1 (ko) 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
SE510813C2 (sv) * 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP2001097870A (ja) * 1999-09-30 2001-04-10 Snow Brand Milk Prod Co Ltd 乳酸菌を利用した胆汁酸の吸着方法
JP2001292728A (ja) 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US6383482B1 (en) 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6963306B2 (en) * 2001-02-02 2005-11-08 Rosum Corp. Position location and data transmission using pseudo digital television transmitters
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US6565847B1 (en) 2002-07-03 2003-05-20 Vitacost.Com, Inc. Thermogenic weight management composition
US20040014403A1 (en) * 2002-07-16 2004-01-22 Oberkampf Brandon L. CMP point of use filtration
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
ATE354964T1 (de) * 2003-05-22 2006-03-15 Synbiotics Ab Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US20060093592A1 (en) 2004-10-04 2006-05-04 Nutracea Synbiotics
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage

Also Published As

Publication number Publication date
SI1945235T1 (sl) 2013-02-28
WO2007043933A1 (en) 2007-04-19
EP1945235A4 (en) 2009-11-11
ES2396865T3 (es) 2013-02-28
EA200800913A1 (ru) 2008-10-30
DK1945235T3 (da) 2013-01-14
SE529185C2 (sv) 2007-05-22
CN101287478A (zh) 2008-10-15
AU2006299956A1 (en) 2007-04-19
PL1945235T3 (pl) 2013-03-29
SE0502214L (sv) 2007-04-08
EP1945235A1 (en) 2008-07-23
CY1113704T1 (el) 2016-06-22
EA015461B1 (ru) 2011-08-30
EP2431044A1 (en) 2012-03-21
DK2431044T3 (en) 2016-04-11
PT1945235E (pt) 2013-01-14
EP1945235B1 (en) 2012-09-26
ES2567404T3 (es) 2016-04-22
AU2006299956B2 (en) 2012-03-15
JP2009511469A (ja) 2009-03-19
CN101287478B (zh) 2012-10-03
EP2431044B1 (en) 2016-01-13
CA2624890A1 (en) 2007-04-19
US20080267933A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
BRPI0616993A2 (pt) bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
TWI744479B (zh) 包含雙歧桿菌的組合物及其製備方法
BR112012001812B1 (pt) Uso de bactéria para o tratamento da endotoxemiametabólica em mamífero
CN119174784B (zh) 动物双歧杆菌乳亚种或组合物在制备用于预防和/或治疗代谢性疾病的产品中的应用
KR20140026326A (ko) 신장 기능을 강화시키는 조성물 및 방법
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
JP2024529268A (ja) ラクトバチルス属の菌株３種を含む組成物、およびその用途
CN120390793A (zh) 黏膜乳杆菌和需要glp-1增加的疾病
Reehana et al. Synbiotics in Nutrition
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
MX2008004578A (en) Probiotics to influence fat metabolism and obesity
WO2025098973A1 (en) Bifidobacterium adolescentis for reducing the release of proinflammatory cytokines
Prapaipat et al. World Journal of Advanced Research and Reviews
CN117731008A (zh) 用于改善肠道屏障的组合物
Workouts et al. Probiotic Roundup
Sharma et al. 13 Probiotics and Its Efficacy Assessment in Diabetic Intervention
GÜRÇAY PREBIOTICS AND PROBIOTICS
HK1239568A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1239568A1 (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1239564A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK40001005A (en) Novel probiotics bifidobacteria strains

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25A Requested transfer of rights approved

Owner name: CHR. HANSEN A/S (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2326 DE 04-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.